203 related articles for article (PubMed ID: 36397934)
1. Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single-arm study (STASEY).
Jiménez-Yuste V; Peyvandi F; Klamroth R; Castaman G; Shanmukhaiah C; Rangarajan S; García Chavez J; Martinez R; Kenet G; Alzahrani H; Robson S; Schmitt C; Kiialainen A; Meier O; Ozelo M
Res Pract Thromb Haemost; 2022 Nov; 6(8):e12837. PubMed ID: 36397934
[TBL] [Abstract][Full Text] [Related]
2. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial.
Pipe SW; Collins P; Dhalluin C; Kenet G; Schmitt C; Buri M; Jiménez-Yuste V; Peyvandi F; Young G; Oldenburg J; Mancuso ME; Kavakli K; Kiialainen A; Deb S; Niggli M; Chang T; Lehle M; Fijnvandraat K
Blood; 2024 Apr; 143(14):1355-1364. PubMed ID: 38127586
[TBL] [Abstract][Full Text] [Related]
3. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.
Négrier C; Mahlangu J; Lehle M; Chowdary P; Catalani O; Bernardi RJ; Jiménez-Yuste V; Beckermann BM; Schmitt C; Ventriglia G; Windyga J; d'Oiron R; Moorehead P; Koparkar S; Teodoro V; Shapiro AD; Oldenburg J; Hermans C
Lancet Haematol; 2023 Mar; 10(3):e168-e177. PubMed ID: 36716761
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: A randomized study (HAVEN 5).
Yang R; Wang S; Wang X; Sun J; Chuansumrit A; Zhou J; Schmitt C; Hsu W; Xu J; Li L; Chang T; Zhao X
Res Pract Thromb Haemost; 2022 Feb; 6(2):e12670. PubMed ID: 35284778
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies.
Mahlangu J; Jiménez-Yuste V; Ventriglia G; Niggli M; Barlera S; Hermans C; Lehle M; Chowdary P; Jew L; Windyga J; Frenzel L; Schmitt C; Castaman G; Pipe SW
Res Pract Thromb Haemost; 2024 Feb; 8(2):102364. PubMed ID: 38559572
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
[TBL] [Abstract][Full Text] [Related]
7. Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors.
Castaman G; Peyvandi F; Kremer Hovinga JA; Schutgens REG; Robson S; Moreno K; Jiménez-Yuste V
TH Open; 2024 Jan; 8(1):e42-e54. PubMed ID: 38222041
[No Abstract] [Full Text] [Related]
8. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.
Callaghan MU; Negrier C; Paz-Priel I; Chang T; Chebon S; Lehle M; Mahlangu J; Young G; Kruse-Jarres R; Mancuso ME; Niggli M; Howard M; Bienz NS; Shima M; Jiménez-Yuste V; Schmitt C; Asikanius E; Levy GG; Pipe SW; Oldenburg J
Blood; 2021 Apr; 137(16):2231-2242. PubMed ID: 33512413
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.
Young G; Liesner R; Chang T; Sidonio R; Oldenburg J; Jiménez-Yuste V; Mahlangu J; Kruse-Jarres R; Wang M; Uguen M; Doral MY; Wright LY; Schmitt C; Levy GG; Shima M; Mancuso ME
Blood; 2019 Dec; 134(24):2127-2138. PubMed ID: 31697801
[TBL] [Abstract][Full Text] [Related]
10. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R
N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of emicizumab in preventing bleeding events in severe and moderate hemophilia A: A single-center experience in Bangladesh.
Tory SS; Ghosh S; Nazneen H; Farhad N; Islam S; Hasan MJ; Biswas AR
EJHaem; 2024 Feb; 5(1):39-46. PubMed ID: 38406515
[TBL] [Abstract][Full Text] [Related]
12. Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557
[TBL] [Abstract][Full Text] [Related]
13. Emicizumab use in females with moderate or mild hemophilia A without factor VIII inhibitors who warrant prophylaxis.
Hermans C; Ventriglia G; Obaji S; Beckermann BM; Lehle M; Catalani O; d'Oiron R; Frenzel L
Res Pract Thromb Haemost; 2023 Nov; 7(8):102239. PubMed ID: 38193069
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial.
Reyes A; Révil C; Niggli M; Chebon S; Schlagmüller S; Flacke JP; Zortel M; Paz-Priel I; Asikanius E; Hampton R; Mahajan A; Schmidt E; Edwards SC
Curr Med Res Opin; 2019 Dec; 35(12):2079-2087. PubMed ID: 31355677
[No Abstract] [Full Text] [Related]
15. Efficacy, safety and cost of emicizumab prophylaxis in haemophilia A patients with inhibitors: A nationwide observational study in Taiwan.
Shen MC; Chou SC; Chiou SS; Lin PC; Chen YC; Lin HY; Lee YC; Huang CE; Weng TF; Huang TH; Chung CY; Chen JS; Chen SH; Cheng SN; Hsiao CC; Huang YM; Chen SH; Yu YB; Lin SC; Lin CY; Peng CT; Wang JD;
Haemophilia; 2023 Nov; 29(6):1499-1508. PubMed ID: 37819166
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors.
Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Kasai R; Yoneyama K; Yoshida H; Nogami K
Blood Adv; 2017 Oct; 1(22):1891-1899. PubMed ID: 29296836
[TBL] [Abstract][Full Text] [Related]
17. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
[No Abstract] [Full Text] [Related]
18. A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A.
Shima M; Amano K; Ogawa Y; Yoneyama K; Ozaki R; Kobayashi R; Sakaida E; Saito M; Okamura T; Ito T; Hattori N; Higasa S; Suzuki N; Seki Y; Nogami K
J Thromb Haemost; 2023 Mar; 21(3):534-545. PubMed ID: 36696195
[TBL] [Abstract][Full Text] [Related]
19. Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors.
Ebbert PT; Xavier F; Seaman CD; Ragni MV
Haemophilia; 2020 Jan; 26(1):41-46. PubMed ID: 31746522
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy of emicizumab for up to 5.8 years and patients' perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A.
Shima M; Nagao A; Taki M; Matsushita T; Oshida K; Amano K; Nagami S; Okada N; Maisawa S; Nogami K
Haemophilia; 2021 Jan; 27(1):81-89. PubMed ID: 33236410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
